Citations (71)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
David Charles Baranowski, Beth Buchanan, Heather C Dwyer, Joseph P Gabriele, Stephanie Kelly & Joseph A Araujo. (2018) Penetration and efficacy of transdermal NSAIDs in a model of acute joint inflammation. Journal of Pain Research 11, pages 2809-2819.
Read now
Read now
Fasina Makkar & Kajal Chakraborty. (2018) Previously undescribed antioxidative azocinyl morpholinone alkaloid from red seaweed Gracilaria opuntia with anti-cyclooxygenase and lipoxygenase properties. Natural Product Research 32:10, pages 1150-1160.
Read now
Read now
Nikolaos Papageorgiou, Effimia Zacharia, Alexandros Briasoulis, Marietta Charakida & Dimitris Tousoulis. (2016) Celecoxib for the treatment of atherosclerosis. Expert Opinion on Investigational Drugs 25:5, pages 619-633.
Read now
Read now
Kay Brune & Paola Patrignani. (2015) New insights into the use of currently available non-steroidal anti-inflammatory drugs. Journal of Pain Research 8, pages 105-118.
Read now
Read now
M.
Komal Reddy, T.
Ravinder Reddy & K.
Raghava Raju. (2010) Novel Synthesis of 2-(2-(3-Hydroxy-5-oxo-4-phenylthiophen-2(5H)-ylidene)-2-phenylacetamido)propanoic Acid Analogues and Their Anti-Inflammatory Properties. Phosphorus, Sulfur, and Silicon and the Related Elements 185:2, pages 313-318.
Read now
Read now
Paola Patrignani, Stefania Tacconelli & Marta L Capone. (2008) Risk management profile of etoricoxib: an example of personalized medicine. Therapeutics and Clinical Risk Management 4:5, pages 983-997.
Read now
Read now
Marta L Capone, Stefania Tacconelli, Luigia Di Francesco, Maria Petrelli & Paola Patrignani. (2008) Cardiovascular effects of valdecoxib: transducing human pharmacology results into clinical read-outs. Expert Opinion on Drug Safety 7:1, pages 29-42.
Read now
Read now
Peter Brooks & Paul Kubler. (2006) Etoricoxib for arthritis and pain management. Therapeutics and Clinical Risk Management 2:1, pages 45-57.
Read now
Read now
Werner Kiefer & Gerd Dannhardt. (2005) COX-2 inhibition and pain management: a review summary. Expert Review of Clinical Immunology 1:3, pages 431-442.
Read now
Read now
Marta L Capone, Stefania Tacconelli & Paola Patrignani. (2005) Clinical pharmacology of etoricoxib. Expert Opinion on Drug Metabolism & Toxicology 1:2, pages 269-282.
Read now
Read now
Cesar R. Ramos-Remus, Elke Hunsche, Panagiotis Mavros, Julio Querol & Rafael Suarez. (2004) Evaluation of quality of life following treatment with etoricoxib in patients with arthritis or low-back pain: an open label, uncontrolled pilot study in Mexico. Current Medical Research and Opinion 20:5, pages 691-698.
Read now
Read now
Michalis V Karamouzis & Athanasios G Papavassiliou. (2004) COX-2 inhibition in cancer therapeutics: a field of controversy or a magic bullet?. Expert Opinion on Investigational Drugs 13:4, pages 359-372.
Read now
Read now
Eduardo Collantes-Estevez & Cristina Fernandez-Perez. (2003) Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain. Current Medical Research and Opinion 19:5, pages 402-410.
Read now
Read now
Articles from other publishers (58)
Silja Hofmann, Johannes Winter, Tobias Prenzel, María de Jesús Gálvez‐Vázquez & Siegfried R. Waldvogel. (2023) Electrochemical Synthesis of Isoxazoles and Isoxazolines via Anodic Oxidation of Oximes. ChemElectroChem 10:22.
Crossref
Crossref
E.J. Halvey, N. Haslam & E.R. Mariano. (2023) Non-steroidal anti-inflammatory drugs in the perioperative period. BJA Education.
Crossref
Crossref
Min-Jeong Kim, Fernanda Juarez Anaya, Lester S Manly, Jae-Hoon Lee, Jinsoo Hong, Stal Shrestha, Sanjay Telu, Katharine Henry, Jose A Montero Santamaria, Jeih-San Liow, Paolo Zanotti-Fregonara, H. Umesha Shetty, Sami S Zoghbi, Victor W. Pike & Robert B. Innis. (2022)
Whole-body PET imaging in humans shows that
11
C-PS13 is selective for cyclooxygenase-1 and can measure the in vivo potency of nonsteroidal anti-inflammatory drugs
. Journal of Nuclear Medicine, pages jnumed.122.264061.
Crossref
Crossref
Austin E. F. Sheppe & Mariola J. Edelmann. (2021) Roles of Eicosanoids in Regulating Inflammation and Neutrophil Migration as an Innate Host Response to Bacterial Infections. Infection and Immunity 89:8.
Crossref
Crossref
Vinuta Kamat, Rangappa Santosh, Boja Poojary, Suresh P. Nayak, Banoth Karan Kumar, Murugesan Sankaranarayanan, Faheem, Sheela Khanapure, Delicia Avilla. Barretto & Shyam K. Vootla. (2020)
Pyridine- and Thiazole-Based Hydrazides with Promising Anti-inflammatory and Antimicrobial Activities along with Their
In Silico
Studies
. ACS Omega 5:39, pages 25228-25239.
Crossref
Crossref
Chris Walker. (2018) Are All Oral COX-2 Selective Inhibitors the Same? A Consideration of Celecoxib, Etoricoxib, and Diclofenac. International Journal of Rheumatology 2018, pages 1-12.
Crossref
Crossref
Katherine N. Theken. (2018) Variability in analgesic response to non-steroidal anti-inflammatory drugs. Prostaglandins & Other Lipid Mediators 139, pages 63-70.
Crossref
Crossref
Sophia Davidson. (2018) Treating Influenza Infection, From Now and Into the Future. Frontiers in Immunology 9.
Crossref
Crossref
Naoto Fujii, Olivia L. Pastore, Gregory W. McGarr, Robert D. Meade, Brendan D. McNeely, Takeshi Nishiyasu & Glen P. Kenny. (2018) Cyclooxygenase-1 and -2 modulate sweating but not cutaneous vasodilation during exercise in the heat in young men. Physiological Reports 6:17, pages e13844.
Crossref
Crossref
Ritika Sachdeva, Abhinav Soni, V. P. Singh & G. S. S. Saini. Reactivity of etoricoxib based on computational study of molecular orbitals, molecular electrostatic potential surface and Mulliken charge analysis. Reactivity of etoricoxib based on computational study of molecular orbitals, molecular electrostatic potential surface and Mulliken charge analysis.
Mohd Fadhlizil Fasihi Mohd Aluwi, Kamal Rullah, Md. Areeful Haque, Bohari M. Yamin, Waqas Ahmad, Muhammad Wahab Amjad, Sze Wei Leong, Nurul Amira Fahmizar, Juriyati Jalil, Faridah Abas, Nor Hadiani Ismail, Ibrahim Jantan & Kok Wai Lam. (2017) Suppression of PGE2 production via disruption of MAPK phosphorylation by unsymmetrical dicarbonyl curcumin derivatives. Medicinal Chemistry Research 26:12, pages 3323-3335.
Crossref
Crossref
Mostafa Somri, Nasir Hawash, Christopher Hadjittofi, Marlain Ghantous-Toukan, Riad Tome, Marina Yodashkin & Ibrahim Matter. (2017) Protective multimodal analgesia with etoricoxib and spinal anesthesia in inguinal hernia repair: a randomized controlled trial. Journal of Anesthesia 31:5, pages 645-650.
Crossref
Crossref
Sanjit Kumar, Imteyaz Qamar & Nagendra Singh. 2005. Encyclopedia of Life Sciences. Encyclopedia of Life Sciences
1
7
.
Teresa Mancilla-Percino, Cynthia R. Trejo-Muñoz, José Alfredo Díaz-Gandarilla, Patricia Talamás-Rohana, José Eduardo Guzmán Ramírez, Jair Cervantes & Armando Figueroa Ortíz. (2016) Isoindoline Derivatives of α-Amino Acids as Cyclooxygenase 1 and 2 Inhibitors. Archiv der Pharmazie 349:3, pages 175-185.
Crossref
Crossref
Matthew A. Schiffler, Stephen Antonysamy, Shobha N. Bhattachar, Kristina M. Campanale, Srinivasan Chandrasekhar, Bradley Condon, Prashant V. Desai, Matthew J. Fisher, Christopher Groshong, Anita Harvey, Michael J. Hickey, Norman E. Hughes, Scott A. Jones, Euibong J. Kim, Steven L. Kuklish, John G. Luz, Bryan H. Norman, Richard E. Rathmell, John R. Rizzo, Thomas W. Seng, Stefan J. Thibodeaux, Timothy A. Woods, Jeremy S. York & Xiao-Peng Yu. (2015) Discovery and Characterization of 2-Acylaminoimidazole Microsomal Prostaglandin E Synthase-1 Inhibitors. Journal of Medicinal Chemistry 59:1, pages 194-205.
Crossref
Crossref
K. Brune, B. Renner & G. Tiegs. (2015) Acetaminophen/paracetamol: A history of errors, failures and false decisions. European Journal of Pain 19:7, pages 953-965.
Crossref
Crossref
Delia Mandracchia, Adriana Trapani, Theodora Chlapanidas, Giuseppe Trapani & Giuseppe Tripodo. (2015) Enzyme controlled release of celecoxib from inulin based nanomicelles. Journal of Cellular Biotechnology 1:1, pages 107-118.
Crossref
Crossref
Avaneesh K. Dwivedi, Vaishali Gurjar, Sanjit Kumar & Nagendra Singh. (2015) Molecular basis for nonspecificity of nonsteroidal anti-inflammatory drugs (NSAIDs). Drug Discovery Today 20:7, pages 863-873.
Crossref
Crossref
Wenyin LohHwee Hoon LimRajeshwar RaoAnne GohLin Xin OngWen Chin Chiang. (2015) Tolerance to etoricoxib in children with nonsteroidal anti-inflammatory drug hypersensitivity. Asia Pacific Allergy 5:1, pages 40.
Crossref
Crossref
Thota Ganesh. (2013) Prostanoid Receptor EP2 as a Therapeutic Target. Journal of Medicinal Chemistry 57:11, pages 4454-4465.
Crossref
Crossref
Lisa Felden, Carmen Walter, Carlo Angioni, Yannick Schreiber, Nils von Hentig, Nerea Ferreiros, Gerd Geisslinger & Jörn Lötsch. (2014) Similar Maximum Systemic but not Local Cyclooxygenase-2 Inhibition by 50 mg Lumiracoxib and 90 mg Etoricoxib: A Randomized Controlled Trial in Healthy Subjects. Pharmaceutical Research.
Crossref
Crossref
Anand D. Tiwari, Siva S. Panda, Adel S. Girgis, Sandhyamayee Sahu, Riham F. George, Aladdin M. Srour, Brian La Starza, Abdullah M. Asiri, C. Dennis Hall & Alan R. Katritzky. (2014) Microwave assisted synthesis and QSAR study of novel NSAID acetaminophen conjugates with amino acid linkers. Organic & Biomolecular Chemistry 12:37, pages 7238.
Crossref
Crossref
Michal Bachar, Amitai Mandelbaum, Irina Portnaya, Hadas Perlstein, Simcha Even-Chen, Yechezkel Barenholz & Dganit Danino. (2012) Development and characterization of a novel drug nanocarrier for oral delivery, based on self-assembled β-casein micelles. Journal of Controlled Release 160:2, pages 164-171.
Crossref
Crossref
Li Gong, Caroline F. Thorn, Monica M. Bertagnolli, Tilo Grosser, Russ B. Altman & Teri E. Klein. (2012) Celecoxib pathways. Pharmacogenetics and Genomics 22:4, pages 310-318.
Crossref
Crossref
Adel S. Girgis, Srinivasa R. Tala, Polina V. Oliferenko, Alexander A. Oliferenko & Alan R. Katritzky. (2012) Computer-assisted rational design, synthesis, and bioassay of non-steroidal anti-inflammatory agents. European Journal of Medicinal Chemistry 50, pages 1-8.
Crossref
Crossref
Mariangela Biava, Giulio Cesare Porretta, Giovanna Poce, Claudio Battilocchio, Salvatore Alfonso, Michele Rovini, Salvatore Valenti, Gianluca Giorgi, Vincenzo Calderone, Alma Martelli, Lara Testai, Lidia Sautebin, Antonietta Rossi, Giuseppina Papa, Carla Ghelardini, Lorenzo Di Cesare Mannelli, Antonio Giordani, Paola Anzellotti, Annalisa Bruno, Paola Patrignani & Maurizio Anzini. (2011) Novel Analgesic/Anti-Inflammatory Agents: Diarylpyrrole Acetic Esters Endowed with Nitric Oxide Releasing Properties. Journal of Medicinal Chemistry 54:22, pages 7759-7771.
Crossref
Crossref
A Rossi, C Pergola, A Koeberle, M Hoffmann, F Dehm, P Bramanti, S Cuzzocrea, O Werz & L Sautebin. (2010) The 5-lipoxygenase inhibitor, zileuton, suppresses prostaglandin biosynthesis by inhibition of arachidonic acid release in macrophages. British Journal of Pharmacology 161:3, pages 555-570.
Crossref
Crossref
Maria Cecilia Anauate, Luce Maria Torres & Suzana Beatriz Veríssimo de Mello. (2010)
Effect of isolated fractions of
Harpagophytum procumbens
D.C. (devil's claw) on COX‐1, COX‐2 activity and nitric oxide production on whole‐blood assay
. Phytotherapy Research 24:9, pages 1365-1369.
Crossref
Crossref
Nicholas A. Burd, Jared M. Dickinson, Jennifer K. LeMoine, Chad C. Carroll, Bridget E. Sullivan, Jacob M. Haus, Bozena Jemiolo, Scott W. Trappe, Gordon M. Hughes, Charles E. SandersJr.Jr. & Todd A. Trappe. (2010) Effect of a cyclooxygenase-2 inhibitor on postexercise muscle protein synthesis in humans. American Journal of Physiology-Endocrinology and Metabolism 298:2, pages E354-E361.
Crossref
Crossref
Bertold Renner, Josef Zacher, Asokumar Buvanendran, Gerrit Walter, Jochen Strauss & Kay Brune. (2010) Absorption and distribution of etoricoxib in plasma, CSF, and wound tissue in patients following hip surgery—a pilot study. Naunyn-Schmiedeberg's Archives of Pharmacology 381:2, pages 127-136.
Crossref
Crossref
Matteo Fornai, Luca Antonioli, Rocchina Colucci, Nunzia Bernardini, Narcisa Ghisu, Marco Tuccori, Roberto De Giorgio, Mario Del Tacca & Corrado Blandizzi. (2010) Emerging role of cyclooxygenase isoforms in the control of gastrointestinal neuromuscular functions. Pharmacology & Therapeutics 125:1, pages 62-78.
Crossref
Crossref
James M. Ritter, Idris Harding & John B. Warren. (2009) Precaution, cyclooxygenase inhibition, and cardiovascular risk. Trends in Pharmacological Sciences 30:10, pages 503-508.
Crossref
Crossref
Martin E. Swarbrick, Paul J. Beswick, Robert J. Gleave, Richard H. Green, Sharon Bingham, Chas Bountra, Malcolm C. Carter, Laura J. Chambers, Iain P. Chessell, Nick M. Clayton, Sue D. Collins, John A. Corfield, C. David Hartley, Savvas Kleanthous, Paul F. Lambeth, Fiona S. Lucas, Neil Mathews, Alan Naylor, Lee W. Page, Jeremy J. Payne, Neil A. Pegg, Helen S. Price, John Skidmore, Alexander J. Stevens, Richard Stocker, Sharon C. Stratton, Alastair J. Stuart & Joanne O. Wiseman. (2009) Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors. Bioorganic & Medicinal Chemistry Letters 19:15, pages 4504-4508.
Crossref
Crossref
Hao-Chieh Chiu, Jian Yang, Shilpa Soni, Samuel K. Kulp, John S. Gunn, Larry S. Schlesinger & Ching-Shih Chen. (2009)
Pharmacological Exploitation of an Off-Target Antibacterial Effect of the Cyclooxygenase-2 Inhibitor Celecoxib against
Francisella tularensis
. Antimicrobial Agents and Chemotherapy 53:7, pages 2998-3002.
Crossref
Crossref
Corrado Blandizzi, Marco Tuccori, Rocchina Colucci, Matteo Fornai, Luca Antonioli, Narcisa Ghisu & Mario Del Tacca. (2009) Role of coxibs in the strategies for gastrointestinal protection in patients requiring chronic non-steroidal anti-inflammatory therapy. Pharmacological Research 59:2, pages 90-100.
Crossref
Crossref
Maurizio AnziniMichele RoviniAndrea CappelliSalvatore VomeroFabrizio ManettiMaurizio BottaLidia SautebinAntonietta RossiCarlo PergolaCarla GhelardiniMonica NorciniAntonio GiordaniFrancesco MakovecPaola AnzellottiPaola PatrignaniMariangela Biava. (2008) Synthesis, Biological Evaluation, and Enzyme Docking Simulations of 1,5-Diarylpyrrole-3-Alkoxyethyl Ethers as Selective Cyclooxygenase-2 Inhibitors Endowed with Anti-inflammatory and Antinociceptive Activity. Journal of Medicinal Chemistry 51:15, pages 4476-4481.
Crossref
Crossref
Christopher M. Herndon, Rob W. Hutchison, Hildegarde J. Berdine, Zachary A. Stacy, Judy T. Chen, David D. Farnsworth, Devra Dang & Joli D. Fermo. (2012) Management of Chronic Nonmalignant Pain with Nonsteroidal Antiinflammatory Drugs. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 28:6, pages 788-805.
Crossref
Crossref
Anja-Kristina BrustHolger K. UlbrichGail M. SeigelNorbert PfeifferFranz H. Grus. (2008) Effects of Cyclooxygenase Inhibitors on Apoptotic Neuroretinal Cells. Biomarker Insights 3, pages BMI.S692.
Crossref
Crossref
Alejandro Escudero-Contreras, Janitzia Vazquez-Mellado Cervantes & Eduardo Collantes-Estevez. (2007) Update on the clinical pharmacology of etoricoxib, a potent cyclooxygenase-2 inhibitor. Future Rheumatology 2:6, pages 545-565.
Crossref
Crossref
Colin D Funk & Garret A FitzGerald. (2007) COX-2 Inhibitors and Cardiovascular Risk. Journal of Cardiovascular Pharmacology 50:5, pages 470-479.
Crossref
Crossref
Valerie Kvaternick, Thomas Malinski, Jill Wortmann & James Fischer. (2007) Quantitative HPLC-UV method for the determination of firocoxib from horse and dog plasma. Journal of Chromatography B 854:1-2, pages 313-319.
Crossref
Crossref
V. R. Khairullina, A. D. Mukhametov, G. G. Garifullina, A. Ya. Gerchikov, L. A. Tyurina & F. S. Zarudii. (2007) Computer analysis of structure-activity relationship for selective and nonselective inhibitors of cyclooxygenases 1 and 2. Pharmaceutical Chemistry Journal 41:4, pages 216-221.
Crossref
Crossref
Adel S. Girgis, Nawal Mishriky, Mohey Ellithey, Hanaa M. Hosni & Hanaa Farag. (2007) Novel synthesis of [1]-benzothiepino[5,4-b]pyridine-3-carbonitriles and their anti-inflammatory properties. Bioorganic & Medicinal Chemistry 15:6, pages 2403-2413.
Crossref
Crossref
Marta L. Capone, Stefania Tacconelli, Luigia Di Francesco, Andrea Sacchetti, Maria G. Sciulli & Paola Patrignani. (2007) Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins & Other Lipid Mediators 82:1-4, pages 85-94.
Crossref
Crossref
Hemant Kumar Jain, V.K. Mourya & R.K. Agrawal. (2006) Inhibitory mode of 2-acetoxyphenyl alkyl sulfides against COX-1 and COX-2: QSAR analyses. Bioorganic & Medicinal Chemistry Letters 16:20, pages 5280-5284.
Crossref
Crossref
Wei-Jern Tsai, Young-Ji Shiao, Shwu-Jiuan Lin, Wen-Fei Chiou, Lie-Chwen Lin, Tsang-Hsiung Yang, Che-Ming Teng, Tain-Shung Wu & Li-Ming Yang. (2006) Selective COX-2 inhibitors. Part 1: Synthesis and biological evaluation of phenylazobenzenesulfonamides. Bioorganic & Medicinal Chemistry Letters 16:17, pages 4440-4443.
Crossref
Crossref
E Munsterhjelm, T.T. Niemi, O Ylikorkala, P.J. Neuvonen & P.H. Rosenberg. (2006) Influence on platelet aggregation of i.v. parecoxib and acetaminophen in healthy volunteers. British Journal of Anaesthesia 97:2, pages 226-231.
Crossref
Crossref
Zachary A Stacy, Paul P Dobesh & Toby C Trujillo. (2006) Cardiovascular Risks of Cyclooxygenase Inhibition. Pharmacotherapy 26:7, pages 919-938.
Crossref
Crossref
Marek L Kowalski & Joanna Makowska. (2006) Use of Nonsteroidal Anti-Inflammatory Drugs in Patients with Aspirin Hypersensitivity. Treatments in Respiratory Medicine 5:6, pages 399-406.
Crossref
Crossref
Susanne Fries, Tilo Grosser, Thomas S. Price, John A. Lawson, Shiv Kapoor, Susan DeMarco, Mathew T. Pletcher, Tim Wiltshire & Garret A. FitzGerald. (2006) Marked Interindividual Variability in the Response to Selective Inhibitors of Cyclooxygenase-2. Gastroenterology 130:1, pages 55-64.
Crossref
Crossref
Burkhard Hinz, Harald Dormann & Kay Brune. (2006) More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib. Arthritis & Rheumatism 54:1, pages 282-291.
Crossref
Crossref
Mario Sánchez-Borges, Fernan Caballero-Fonseca & Arnaldo Capriles-Hulett. (2005) Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug–induced urticaria and angioedema. Annals of Allergy, Asthma & Immunology 95:2, pages 154-158.
Crossref
Crossref
Stuart J Warden. (2005) Cyclo-Oxygenase-2 Inhibitors. Sports Medicine 35:4, pages 271-283.
Crossref
Crossref
F. Berenbaum. (2005) VIOXX et complications cardiovasculaires : une affaire de famille ?. Revue du Rhumatisme 72:1, pages 1-3.
Crossref
Crossref
Francis Berenbaum. (2005) VIOXX and cardiovascular events: a class effect?. Joint Bone Spine 72:1, pages 1-3.
Crossref
Crossref
Marek Murias, Norbert Handler, Thomas Erker, Karin Pleban, Gerhard Ecker, Philipp Saiko, Thomas Szekeres & Walter Jäger. (2004) Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure–activity relationship. Bioorganic & Medicinal Chemistry 12:21, pages 5571-5578.
Crossref
Crossref
Leonardo Di Nunno, Paola Vitale, Antonio Scilimati, Stefania Tacconelli & Paola Patrignani. (2004) Novel Synthesis of 3,4-Diarylisoxazole Analogues of Valdecoxib: Reversal Cyclooxygenase-2 Selectivity by Sulfonamide Group Removal. Journal of Medicinal Chemistry 47:20, pages 4881-4890.
Crossref
Crossref
Yuhong Yuan & Richard H. Hunt. (2003) Assessment of the safety of selective cyclo-oxygenase-2 inhibitors: where are we in 2003?. InflammoPharmacology 11:4-6, pages 337-354.
Crossref
Crossref